MM
VRTX icon

MQS Management’s Vertex Pharmaceuticals VRTX Stock Holding History

MQS Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-950
Closed -$423K – 679
2025
Q2 		$423K Buy
+950
New +$438K 0.23% 168
2024
Q4 		– Sell
-1,358
Closed -$632K – 395
2024
Q3 		$632K Buy
1,358
+62
+5% +$29.8K 0.35% 76
2024
Q2 		$607K Buy
1,296
+335
+35% +$145K 0.37% 67
2024
Q1 		$402K Buy
+961
New +$406K 0.23% 175
2023
Q1 		– Sell
-2,427
Closed -$701K – 611
2022
Q4 		$701K Buy
+2,427
New +$740K 0.48% 42

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

MQS Management's VRTX Position: Q3 2025 in Review

MQS Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 950 shares — an estimated $423K sold.

MQS Management first reported a position in VRTX in Q4 2022 and held it in 5 quarters. The position peaked at $701K in Q4 2022. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • MQS Management reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • MQS Management sold 950 Vertex Pharmaceuticals shares in Q3 2025, an estimated $423K.
  • MQS Management first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • MQS Management's Vertex Pharmaceuticals position peaked at $701K in Q4 2022.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on MQS Management's 13F filing for Q3 2025, filed 6 Nov 2025.